Realizing Effectiveness Across Continents With Hydroxyurea (REACH)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

635

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

July 1, 2018

Study Completion Date

August 31, 2033

Conditions
Sickle Cell Disease
Interventions
DRUG

Hydroxyurea

Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.

Trial Locations (4)

Unknown

Hospital Pediátrico David Bernardino, Luanda

Centre Hospitalier Monkole, Kinshasa

KEMRI/Wellcome Trust Research, Kilifi

Ministry of Health Mbale Regional Hospital, Mbale

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT01966731 - Realizing Effectiveness Across Continents With Hydroxyurea (REACH) | Biotech Hunter | Biotech Hunter